Eton Pharmaceuticals (ETON) Q2 2025 earnings summary

Executive summary

• Achieved Q2 2025 revenues of $18.9M, up 108% year-over-year, driven by strong commercial execution and new product launches including KHINDIVI, INCRELEX, and GALZIN.

• Gross profit for Q2 2025 was $11.9M, nearly doubling from $5.6M in Q2 2024; adjusted gross margin improved to 75% from 65% year-over-year.

• Adjusted EBITDA was $3.1M, up from negative $1.6M in Q2 2024; non-GAAP net income was $1.5M, compared to a net loss of $1.9M in the prior year.

• Cash and equivalents stood at $25.4M as of June 30, 2025, with $8M operating cash flow generated in Q2 and a subsequent $4.6M inflow from licensing.

• Projected to reach $80M annual revenue run rate in Q3 2025, ahead of previous guidance.

Financial highlights

• Q2 2025 revenue reached $18.9M, compared to $9.1M in Q2 2024, a 108% increase.

• Adjusted gross profit was $14.1M (75% margin), up from $5.9M (65% margin) year-over-year.

• Adjusted EBITDA was $3.1M, compared to negative $1.6M in Q2 2024.

• Non-GAAP net income was $1.5M, versus a net loss of $1.9M in the prior year period.

• Cash and cash equivalents as of June 30, 2025, were $25.4M, with $8M operating cash flow in Q2.

Outlook and guidance

• Now expects to reach $80M annual revenue run rate in Q3 2025, ahead of prior guidance.

• Full-year 2025 adjusted gross margin expected at ~70%, with a long-term target of 75% by 2028.

• Adjusted G&A expenses projected to remain flat or decline in the second half of 2025.

• Management expects existing cash and product revenues to fund operations and capital expenditures for at least the next twelve months.

• Anticipating potential approval and launch of ET-600 in Q1 2026.